Skip to main content
SpringerLink
Log in

Prognosefaktoren beim Lungenkarzinom

Prognostic factors in lung cancer

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Das Lungenkarzinom hat weiterhin eine sehr schlechte Prognose. Um Ausmaß und Art der Therapie adäquat zu gestalten, werden Prognosefaktoren gesucht. Von den klassischen Faktoren sind dies neben der Einteilung in kleinzellige und nichtkleinzellige Tumoren, die Tumorausbreitung, der Allgemeinzustand und der Gewichtsverlust. Molekularbiologische Faktoren wie p53, bcl2, Gefäßdichte und VEGF haben Einfluss auf die Prognose, erreichen aber nur in Kombination in etwa die Trennschärfe der klassischen Faktoren. Das Wissen um die Biologie des Tumors wird eine erhebliche Rolle für die individuelle Therapie spielen.

Abstract

Lung cancer still has a poor prognosis. In order to apply an adequate type and degree of therapy, factors of prognostic relevance are needed. Apart from the distinction between small and non-small cell lung cancer, classic variables are the extent of the tumour, performance status and weight loss. Molecular biological factors, for example, p53, bcl2, microvessel density and VEGF, also have prognostic relevance, however, these parameters only reach the accuracy of the classic factors in combination. Biological science will play an essential role in adapting therapy to the individual tumour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aitman TJ (2001) DNA microarrays in medical practice. BMJ 323:611–615

    Google Scholar 

  2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1990) Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patients Southwest Oncology Group data base. J Clin Oncol 8:1563–1574

    Google Scholar 

  3. Breathnach OS, Freidlin B, Conley B et al. (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742

    Google Scholar 

  4. Bremnes RM, Sundstrom S, Aasebo U et al. (2003) The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39:303–313

    Google Scholar 

  5. Cox G, Jones JL, Andi A et al. (2001) A biological staging model for operable non-small cell lung cancer. Thorax 56:561–566

    Google Scholar 

  6. Feld R, Sagman U, LeBlanc M (1996) Staging and prognostic factors: small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds) Lung cancer: principles and practice. Lippincott-Raven, Philadelphia, pp 495–509

  7. Fontanini G, Faviana P, Lucchi M et al. (2002) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86:558–563

    Google Scholar 

  8. Gessner C, Kuhn H, Toepfer K et al. (2004) Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer 43:215—222

    Google Scholar 

  9. Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22:777–784

    Google Scholar 

  10. González-Quevedo R, Iniesta P, Morán A et al. (2002) Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J Clin Onc 20:254–262

    Google Scholar 

  11. Hasturk S, Kemp B, Kalapurakal SK et al. (2002) Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 94:1023–1031

    Google Scholar 

  12. Hoang T, Xu E, Schiller JH et al. (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group Data. J Clin Oncol 23:175–183

    Google Scholar 

  13. Hyde L, Wolf J, McCracken S, Yesner R (1973) Natural course of inoperable lung cancer. Chest 64:309–312

    CAS  PubMed  Google Scholar 

  14. Jheon S, Hyun DS, Lee SC et al. (2004) Lung cancer detection by a RT-nested PCR using MAGE A1–6 common primers. Lung Cancer 43:29–37

    Google Scholar 

  15. Khuri FR (2003) Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer 5:S36–40

    Google Scholar 

  16. Livingston RB (1980) Small cell carcinoma of the lung. Blood 56:575–584

    Google Scholar 

  17. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  18. Martin B, Paesmans M, Berghmans T et al. (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89:55–64

    Google Scholar 

  19. Mascaux C, Iannino N, Martin B et al. (2004) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer, doi:10.1038/sj.bjc.6602258

  20. Meert AP, Paesmans M, Martin B et al. (2002) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87:694–701

    Google Scholar 

  21. Miozzo M, Sozzi G, Musso K et al. (1996) Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 56:2285–2288

    Google Scholar 

  22. Monzo M, Rosell R, Sánchez JJ et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786–1793

    Google Scholar 

  23. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    CAS  PubMed  Google Scholar 

  24. Osterlind K (1995) Chemotherapy in small cell lung cancer. Eur Respir Mon 1:306–331

    Google Scholar 

  25. Passlick B, Kubuschok B, Izbicki JR et al. (1999) Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 68:2053–2058

    Google Scholar 

  26. Polyak K, Riggins GJ (2001) Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J Clin Oncol 19:2948–2958

    Google Scholar 

  27. Radzikowska E, Glaz P, Roszkowski K (2002) Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20.561 cases. Ann Oncol 13:1087–1093

    Google Scholar 

  28. Rosell R, Taron M, O’Brate A (2001) Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol 13:101–109

    Google Scholar 

  29. Skuladottir H, Olsen JH (2001) Epidemiology of lung cancer. Eur Respir Mon 6:1–12

    Google Scholar 

  30. Soria JC, Brisgand D, Le Chevalier T (2001) Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12:1667–1670

    Google Scholar 

  31. Steels E, Paesmans M, Berghmans T et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719

    Google Scholar 

  32. Swinson DEB, Jones JL, Richardson D et al. (2002) Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 37:235–240

    Google Scholar 

  33. Tockman MS, Mulshine JL, Piantadosi S et al. (1997) Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 12:2237–2246

    Google Scholar 

  34. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. (1999) Prognostic importance of the standardized uptake value on18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 17:3201–3206

    CAS  PubMed  Google Scholar 

  35. Yanagisawa K, Shyr Y, Xu BJ et al. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Pneumologie, Klinikum der Universität München—Innenstadt

    R. M. Huber

  2. Pneumologie, Klinikum der Universität München—Innenstadt, Ziemssenstraße 1, 80336 , München

    R. M. Huber

Authors
  1. R. M. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. M. Huber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huber, R.M. Prognosefaktoren beim Lungenkarzinom. Pneumologe 2, 77–82 (2005). https://doi.org/10.1007/s10405-005-0027-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-005-0027-2

Schlüsselwörter

Keywords

Search

Navigation